Skip to main content
English
ไทย
Log In
Log in
Communities & Collections
All of SWU IR
SWU Journals
Statistics
About Us
Feedback
Home
SWU Articles from Academic Databases
Articles from Academic Databases : SCOPUS
Scopus: Year 1983-2021
Molecular docking studies of chromone derivatives against wild type and mutant strains of HIV-1 protease
Publication:
Molecular docking studies of chromone derivatives against wild type and mutant strains of HIV-1 protease
0
0
Issued Date
2014
Resource Type
Article
File Type
application/pdf
ISSN
10542523
DOI
10.1007/s00044-014-0992-2
Other identifier(s)
2-s2.0-84896434812
Rights Holder(s)
Scopus
Bibliographic Citation
Medicinal Chemistry Research. Vol 23, No.9 (2014), p.4198-4208
Suggested Citation
APA
IEEE
MLA
Chicago
Vancouver
Nunthanavanit P., Ungwitayatorn J.
Molecular docking studies of chromone derivatives against wild type and mutant strains of HIV-1 protease.
Medicinal Chemistry Research. Vol 23, No.9 (2014), p.4198-4208.
doi:10.1007/s00044-014-0992-2
Retrieved from:
https://hdl.handle.net/20.500.14740/6503
Title
Molecular docking studies of chromone derivatives against wild type and mutant strains of HIV-1 protease
Author(s)
Nunthanavanit P.
Ungwitayatorn J.
Abstract
Developing a new HIV-1 protease (HIV-1 PR) inhibitor is still a challenging task to overcome the drug resistance mutations in the HIV-PR. In this study, docking simulations of chromone derivatives against wild type and eleven mutant variants HIV-1 PR were investigated using GOLD and Autodock programs. From both GOLD and Autodock results, chromone 3, the experimentally observed highly potent HIV-1 PR inhibitor, showed stronger binding affinity against every studied mutant strain (2AVS, 2AVO, 2AVV, 1MES, 1MET, 1MEU, 1SDU, 1SDV, 1C6Y, 2F8O, and 1SH9) than the wild-type enzyme (1AJX). Chromone 32, another potent inhibitor as well as chromones 33, 34, 37, and 47 also showed high binding interaction with several mutant-type enzymes. The coherent picture of the interactions at the active sites of mutant PR should facilitate the further design and development of new potent inhibitor against multidrug-resistant virus. © 2014 Springer Science+Business Media New York.
View online Resources
Research Projects
Organizational Units
Journal Issue
URI
https://hdl.handle.net/20.500.14740/6503
Collections
Scopus: Year 1983-2021
Endorsement
Review
Supplemented By
Referenced By
Full item page